Skip to main content

Table 2 Primary Outcome, treatment outcomes and interventions

From: A double-blind, randomized controlled trial to explore oral tranexamic acid as adjunct for the treatment for postpartum hemorrhage

 

Placebo

N = 128

TXA

N = 130

Bleeding controlled with treatment only –(no additional intervention)a

77 (60.2)

74 (56.9)

Bleeding controlled with treatment only –(no additional serious intervention)b

102 (79.7)

108 (83.1)

Additional interventions

 Oxytocin

37 (28.9)

39 (30.0)

  IV

25 (19.5)

25 (19.2)

  IM

12 (9.4)

14 (10.8)

Ergometrine

34 (26.6)

34 (26.2)

Syntocinon

1 (0.8)

1 (0.8)

Carbetocin IV

10 (7.8)

14 (10.8)

Misoprostol

0 (0.)

1 (0.8)

TXA IV

16 (12.5)

17 (13.1)

Uterine evacuation (MVA)

0 (0.0)

1 (0.8)

Bimanual compression

8 (6.3)

8 (6.2)

Suturing

111 (86.7)

108 (83.1)

Uterine packing

15 (11.7)

10 (7.7)

Blood transfusion

13 (10.2)

12 (9.2)

Uterine artery ligature

1 (0.8)

0 (0)

Hysterectomy

1 (0.8)

0 (0)

Tissue repair

2 (1.6)

1 (0.8)

Plasma expanders

4 (3.1)

3 (2.3)

  1. There were no statistically significant differences between the two groups for any of these variables
  2. aadditional interventions include: uterotonics, TXA, bimanual compression, uterine evacuation, uterine packing, blood transfusion, uterine artery ligation, hysterectomy, tissue repair, plasma expanders. Suturing and administration of IV fluids were excluded
  3. b additional serious interventions calculated as all interventions excluding uterotonics, TXA, bimanual compression, suturing and fluids (serious interventions only)